SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Shilpa Medicare - Quaterly Results

11 Nov 2022 Evaluate
Net sales declined -24.68%  to  Rs. 687.31 million from Rs. 912.47 millions.The Net Loss for the quarter ended September 2022 is Rs. -196.25 millions as compared to Net Profit of Rs. 100.63 millions of corresponding quarter ended September 2021Operating profit Margin for the quarter ended September 2022 slipped to -63.88% as compared to 119.96% of corresponding quarter ended September 2021


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 687.31 912.47 -24.68 1295.65 1967.47 -34.15 3569.52 2570.50 38.86
Other Income 180.87 88.75 103.80 307.15 182.73 68.09 408.62 322.46 26.72
PBIDT -63.88 119.96 -153.25 107.42 342.23 -68.61 625.49 656.16 -4.67
Interest 49.17 31.52 56.00 75.76 56.42 34.28 90.54 60.74 49.06
PBDT -118.91 177.53 -166.98 25.80 374.90 -93.12 623.04 1124.90 -44.61
Depreciation 118.91 83.64 42.17 223.12 154.74 44.19 348.18 222.81 56.27
PBT -237.82 93.89 -353.30 -197.32 220.16 -189.63 274.86 902.09 -69.53
TAX -41.57 -6.74 516.77 -39.61 31.04 -227.61 73.27 251.17 -70.83
Deferred Tax 18.39 9.75 88.62 13.25 14.63 -9.43 25.25 93.37 -72.96
PAT -196.25 100.63 -295.02 -157.71 189.12 -183.39 201.59 650.92 -69.03
Equity 86.80 81.53 6.46 86.80 81.53 6.46 86.80 81.53 6.46
PBIDTM(%) -9.29 13.15 -170.70 8.29 17.39 -52.34 17.52 25.53 -31.35

Shilpa Medicare Share Price

411.55 0.30 (0.07%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×